U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H21ClF3NO4S
Molecular Weight 511.941
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-299897

SMILES

C[C@@H](N(C1=C(F)C=CC(F)=C1)S(=O)(=O)C2=CC=C(Cl)C=C2)C3=C(CCCC(O)=O)C=C(F)C=C3

InChI

InChIKey=IZAOBRWCUGOKNH-OAHLLOKOSA-N
InChI=1S/C24H21ClF3NO4S/c1-15(21-11-7-18(26)13-16(21)3-2-4-24(30)31)29(23-14-19(27)8-12-22(23)28)34(32,33)20-9-5-17(25)6-10-20/h5-15H,2-4H2,1H3,(H,30,31)/t15-/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H21ClF3NO4S
Molecular Weight 511.941
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15670587

BMS-299897 is an orally bioavailable, sulfonamide γ-secretase inhibitor with an IC50 of 7 nM for Aβ production inhibition in HEK293 cells stably overexpressing amyloid precursor protein (APP). BMS-299897 has the potential for treatment of Alzheimer's disease.

CNS Activity

Curator's Comment: BMS-299897 markedly reduced both brain and plasma Abeta(1-40) in APP-YAC mice and in guinea pigs. Readily crosses blood–brain barrier.

Originator

Curator's Comment: # Bristol-Myers Squibb

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
12.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4740 ng/mL
30 mg/kg single, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
4037 ng/mL
15 mg/kg single, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3232 ng/mL
15 mg/kg single, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Cavia porcellus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1629 ng/mL
25 mg/kg single, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Macaca fascicularis
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4014 ng × h/mL
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
9685 ng × h/mL
30 mg/kg single, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
27478 ng × h/mL
15 mg/kg single, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7400 ng × h/mL
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
16778 ng × h/mL
15 mg/kg single, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Cavia porcellus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
3341 ng × h/mL
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Cavia porcellus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6835 ng × h/mL
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Macaca fascicularis
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
8309 ng × h/mL
25 mg/kg single, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Macaca fascicularis
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5.2 h
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
18 h
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Cavia porcellus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.3 h
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Macaca fascicularis
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.5%
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.5%
15 mg/kg single, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BMS-299897 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
PubMed

PubMed

TitleDatePubMed
A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP.
2015
Advances in recent patent and clinical trial drug development for Alzheimer's disease.
2014-07
Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
2005-02-15
Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
2005-02
Patents

Sample Use Guides

Mice: 100 mg/kg po, guinea pigs: 30 mg/kg intraperitoneally
Route of Administration: Other
At ∼1.0 uM, BMS-299897 decreased Aβ42, Aβ40 and Aβ38 peptides to levels ranging from 20 to 50% of the vehicle control in rat neuronal cultures.
Substance Class Chemical
Created
by admin
on Wed Apr 02 08:02:22 GMT 2025
Edited
by admin
on Wed Apr 02 08:02:22 GMT 2025
Record UNII
QK855F579S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-299897
Common Name English
2-((1R)-1-((4-CHLOROPHENYL)SULFONYL)(2,5-DIFLUOROPHENYL) AMINO)ETHYL-5-FLUOROBENZENEBUTANOIC ACID
Preferred Name English
Code System Code Type Description
PUBCHEM
11249248
Created by admin on Wed Apr 02 08:02:22 GMT 2025 , Edited by admin on Wed Apr 02 08:02:22 GMT 2025
PRIMARY
EPA CompTox
DTXSID50460039
Created by admin on Wed Apr 02 08:02:22 GMT 2025 , Edited by admin on Wed Apr 02 08:02:22 GMT 2025
PRIMARY
FDA UNII
QK855F579S
Created by admin on Wed Apr 02 08:02:22 GMT 2025 , Edited by admin on Wed Apr 02 08:02:22 GMT 2025
PRIMARY
CAS
290315-45-6
Created by admin on Wed Apr 02 08:02:22 GMT 2025 , Edited by admin on Wed Apr 02 08:02:22 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY